In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2
Authors:
- Dora BuzasDBDora Buzas
- Adrian H BunzelABAdrian H Bunzel
- Oskar StauferOSOskar Staufer
- Emily J MilodowskiEMEmily J Milodowski
- Grace L EdmundsGEGrace L Edmunds
- Joshua C BuftonJBJoshua C Bufton
- Beatriz V Vidana MateoBMBeatriz V Vidana Mateo
- Sathish K N YadavSYSathish K N Yadav
- Kapil GuptaKGKapil Gupta
- Charlotte FletcherCFCharlotte Fletcher
- Maia K WilliamsonMWMaia K Williamson
- Alexandra HarrisonAHAlexandra Harrison
Open Access
- 1 October 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 6 (4) , 277-297
Abstract
Due to COVID-19, pandemic preparedness emerges as a key imperative, necessitating new approaches to accelerate development of reagents against infectious pathogens. Here, we developed an integrated approach combining synthetic, computational and structural methods with in vitro antibody selection and in vivo immunization to design, produce and validate nature-inspired nanoparticle-based reagents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach resulted in two innovations: (i) a thermostable nasal vaccine called ADDoCoV, displaying multiple copies of a SARS-CoV-2 receptor binding motif derived epitope and (ii) a multivalent nanoparticle superbinder, called Gigabody, against SARS-CoV-2 including immune-evasive variants of concern (VOCs). In vitro generated neutralizing nanobodies and electron cryo-microscopy established authenticity and accessibility of epitopes displayed by ADDoCoV. Gigabody comprising multimerized nanobodies prevented SARS-CoV-2 virion attachment with picomolar EC50. Vaccinating mice resulted in antibodies cross-reacting with VOCs including Delta and Omicron. Our study elucidates Adenovirus-derived dodecamer (ADDomer)-based nanoparticles for use in active and passive immunization and provides a blueprint for crafting reagents to combat respiratory viral infections.Keywords
All Related Versions
Funding Information
- Horizon 2020 (899670)
- European Research Council (834631)
- EPSRC Future Vaccine Manufacturing and Research Hub (EP/R013764/1)
- EPSRC (EP/M022609/1)
- British Society for Antimicrobial Chemotherapy
- MRC (MR/V027506/1, MR/R020566/1, MR/V027506/1)
- United States Food and Drug Administration (HHSF223201510104C)
- Federal Ministry of Education and Research of Germany and the Max Planck Society
- European Research Council (294852)
- Elisabeth Muerer Foundation
- University of Bristol (BB/L01386X/1)
- BBSRC (BB/R000484/1)
- Wellcome Trust (221708/Z/20/Z, 206181/Z/17/Z, 202904/Z/16/Z)
This publication has 81 references indexed in Scilit:
- Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infectionJournal of Controlled Release, 2013
- RELION: Implementation of a Bayesian approach to cryo-EM structure determinationJournal of Structural Biology, 2012
- Modeling Symmetric Macromolecular Structures in Rosetta3PLOS ONE, 2011
- Alternate States of Proteins Revealed by Detailed Energy Landscape MappingJournal of Molecular Biology, 2011
- MolProbity: all-atom structure validation for macromolecular crystallographyActa Crystallographica Section D Structural Biology, 2009
- Sub-angstrom accuracy in protein loop reconstruction by robotics-inspired conformational samplingNature Methods, 2009
- I-TASSER server for protein 3D structure predictionBMC Bioinformatics, 2008
- Prediction of the structure of symmetrical protein assembliesProceedings of the National Academy of Sciences, 2007
- Visualizing density maps with UCSF ChimeraJournal of Structural Biology, 2007
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004